NWK Group’s Alexion Pharmaceuticals ALXN Stock Holding History

NWK Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-35	Closed	-$4K	–	270
2020 Q2	$4K	Buy	+35	New	+$3.72K	﹤0.01%	224

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NWK Group's ALXN Position: Q3 2020 in Review

NWK Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 35 shares — an estimated $4K sold.

NWK Group first reported a position in ALXN in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

NWK Group reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
NWK Group sold 35 Alexion Pharmaceuticals shares in Q3 2020, an estimated $4K.
NWK Group first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 1 quarter.
NWK Group's Alexion Pharmaceuticals position peaked at $4K in Q2 2020.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on NWK Group's 13F filing for Q3 2020, filed 16 Nov 2020.